Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations

Devi Gopinath, William R. Lewis, Luigi Di Biase, Andrea Natale

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Atrial Fibrillation Ablation with Therapeutic Anticoagulation. Pulmonary vein antrum isolation (PVAI) has emerged as an effective treatment for drug-refractory atrial fibrillation (AF). However, thromboembolic events are important complications of this approach. Management of anticoagulation is essential to prevent thromboembolic complications and avoid bleeding complications. The purpose of this review is to outline the general principles followed at our AF centers to address the important issue of pre-, peri-, and postprocedural anticoagulation strategies during PVAI of AF. We initiate warfarin therapy prior to the ablation procedure and continue it through the procedure. Prior work has demonstrated that continuation of therapeutic warfarin during the radiofrequency catheter ablation reduces the risk of periprocedural stroke/transient ischemic attack without increasing the risk of hemorrhagic events. In fact, a strategy that interrupts warfarin anticoagulation may increase the risk of stroke, even with bridging with enoxaparin. Data from our work have shown that minor bleeding was more frequent in the patients bridged with heparin or enoxaparin. There was no significant difference in incidence of major bleeding complications among the patients with a therapeutic level of international normalized ratio (INR) compared with patients for whom bridging therapy was used. Furthermore, the strategy of ablation during a therapeutic INR could be more economical compared with bridging therapy with enoxaparin. Continuation of therapeutic warfarin during ablation of AF may be the best strategy, especially in patients with nonparoxysmal AF, patients with higher thromboembolic risk scores, and patients who require extensive ablation during PVAI of AF.

Original languageEnglish (US)
Pages (from-to)236-239
Number of pages4
JournalJournal of Cardiovascular Electrophysiology
Volume22
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Pulmonary Veins
Warfarin
Atrial Fibrillation
Enoxaparin
International Normalized Ratio
Therapeutics
Hemorrhage
Stroke
Catheter Ablation
Transient Ischemic Attack
Heparin
Incidence

Keywords

  • anticoagulation
  • atrial fibrillation
  • catheter ablation
  • stroke
  • transesophageal echocardiography
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin : Special considerations. / Gopinath, Devi; Lewis, William R.; Di Biase, Luigi; Natale, Andrea.

In: Journal of Cardiovascular Electrophysiology, Vol. 22, No. 2, 02.2011, p. 236-239.

Research output: Contribution to journalArticle

@article{9e74f07381504c9283a5916075a22bf0,
title = "Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations",
abstract = "Atrial Fibrillation Ablation with Therapeutic Anticoagulation. Pulmonary vein antrum isolation (PVAI) has emerged as an effective treatment for drug-refractory atrial fibrillation (AF). However, thromboembolic events are important complications of this approach. Management of anticoagulation is essential to prevent thromboembolic complications and avoid bleeding complications. The purpose of this review is to outline the general principles followed at our AF centers to address the important issue of pre-, peri-, and postprocedural anticoagulation strategies during PVAI of AF. We initiate warfarin therapy prior to the ablation procedure and continue it through the procedure. Prior work has demonstrated that continuation of therapeutic warfarin during the radiofrequency catheter ablation reduces the risk of periprocedural stroke/transient ischemic attack without increasing the risk of hemorrhagic events. In fact, a strategy that interrupts warfarin anticoagulation may increase the risk of stroke, even with bridging with enoxaparin. Data from our work have shown that minor bleeding was more frequent in the patients bridged with heparin or enoxaparin. There was no significant difference in incidence of major bleeding complications among the patients with a therapeutic level of international normalized ratio (INR) compared with patients for whom bridging therapy was used. Furthermore, the strategy of ablation during a therapeutic INR could be more economical compared with bridging therapy with enoxaparin. Continuation of therapeutic warfarin during ablation of AF may be the best strategy, especially in patients with nonparoxysmal AF, patients with higher thromboembolic risk scores, and patients who require extensive ablation during PVAI of AF.",
keywords = "anticoagulation, atrial fibrillation, catheter ablation, stroke, transesophageal echocardiography, warfarin",
author = "Devi Gopinath and Lewis, {William R.} and {Di Biase}, Luigi and Andrea Natale",
year = "2011",
month = "2",
doi = "10.1111/j.1540-8167.2010.01940.x",
language = "English (US)",
volume = "22",
pages = "236--239",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin

T2 - Special considerations

AU - Gopinath, Devi

AU - Lewis, William R.

AU - Di Biase, Luigi

AU - Natale, Andrea

PY - 2011/2

Y1 - 2011/2

N2 - Atrial Fibrillation Ablation with Therapeutic Anticoagulation. Pulmonary vein antrum isolation (PVAI) has emerged as an effective treatment for drug-refractory atrial fibrillation (AF). However, thromboembolic events are important complications of this approach. Management of anticoagulation is essential to prevent thromboembolic complications and avoid bleeding complications. The purpose of this review is to outline the general principles followed at our AF centers to address the important issue of pre-, peri-, and postprocedural anticoagulation strategies during PVAI of AF. We initiate warfarin therapy prior to the ablation procedure and continue it through the procedure. Prior work has demonstrated that continuation of therapeutic warfarin during the radiofrequency catheter ablation reduces the risk of periprocedural stroke/transient ischemic attack without increasing the risk of hemorrhagic events. In fact, a strategy that interrupts warfarin anticoagulation may increase the risk of stroke, even with bridging with enoxaparin. Data from our work have shown that minor bleeding was more frequent in the patients bridged with heparin or enoxaparin. There was no significant difference in incidence of major bleeding complications among the patients with a therapeutic level of international normalized ratio (INR) compared with patients for whom bridging therapy was used. Furthermore, the strategy of ablation during a therapeutic INR could be more economical compared with bridging therapy with enoxaparin. Continuation of therapeutic warfarin during ablation of AF may be the best strategy, especially in patients with nonparoxysmal AF, patients with higher thromboembolic risk scores, and patients who require extensive ablation during PVAI of AF.

AB - Atrial Fibrillation Ablation with Therapeutic Anticoagulation. Pulmonary vein antrum isolation (PVAI) has emerged as an effective treatment for drug-refractory atrial fibrillation (AF). However, thromboembolic events are important complications of this approach. Management of anticoagulation is essential to prevent thromboembolic complications and avoid bleeding complications. The purpose of this review is to outline the general principles followed at our AF centers to address the important issue of pre-, peri-, and postprocedural anticoagulation strategies during PVAI of AF. We initiate warfarin therapy prior to the ablation procedure and continue it through the procedure. Prior work has demonstrated that continuation of therapeutic warfarin during the radiofrequency catheter ablation reduces the risk of periprocedural stroke/transient ischemic attack without increasing the risk of hemorrhagic events. In fact, a strategy that interrupts warfarin anticoagulation may increase the risk of stroke, even with bridging with enoxaparin. Data from our work have shown that minor bleeding was more frequent in the patients bridged with heparin or enoxaparin. There was no significant difference in incidence of major bleeding complications among the patients with a therapeutic level of international normalized ratio (INR) compared with patients for whom bridging therapy was used. Furthermore, the strategy of ablation during a therapeutic INR could be more economical compared with bridging therapy with enoxaparin. Continuation of therapeutic warfarin during ablation of AF may be the best strategy, especially in patients with nonparoxysmal AF, patients with higher thromboembolic risk scores, and patients who require extensive ablation during PVAI of AF.

KW - anticoagulation

KW - atrial fibrillation

KW - catheter ablation

KW - stroke

KW - transesophageal echocardiography

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=79951588485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951588485&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8167.2010.01940.x

DO - 10.1111/j.1540-8167.2010.01940.x

M3 - Article

C2 - 21044211

AN - SCOPUS:79951588485

VL - 22

SP - 236

EP - 239

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 2

ER -